Silo Pharma (SILO) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 14, 2021
Document Information Line Items
Entity Registrant Name	Silo Pharma, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		98,671,970
Amendment Flag	false
Entity Central Index Key	0001514183
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-54872
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 4,636,539	$ 1,128,389
Equity investments	570,200	200
Notes receivable, net		23,500
Prepaid expenses and other current assets - current	230,408	241,091
Inventory	44,665	33,484
Total Current Assets	5,481,812	1,426,664
Prepaid expenses - non-current	19,375
Total Assets	5,501,187	1,426,664
CURRENT LIABILITIES:
Accounts payable and accrued expenses	238,036	127,069
Note payable - current portion	17,837	14,654
Deferred revenue - current portion	68,750
Due to officer - related party	2,366
Total Current Liabilities	326,989	141,723
LONG TERM LIABILITIES:
Deferred revenue - long-term portion	945,312
Note payable - long-term portion	1,063	4,246
Total Long Term Liabilities	946,375	4,246
Total Liabilities	1,273,364	145,969
Commitment and Contingencies (see Note 9)
STOCKHOLDERS' EQUITY:
Preferred stock, value
Common stock, $0.0001 par value, 500,000,000 shares authorized; 85,141,956 and 85,141,956 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	8,514	8,514
Additional paid-in capital	12,316,329	7,034,502
Accumulated deficit	(8,097,020)	(5,762,321)
Total Stockholders' Equity	4,227,823	1,280,695
Total Liabilities and Stockholders' Equity	5,501,187	1,426,664
Series B convertible preferred stock
STOCKHOLDERS' EQUITY:
Preferred stock, value
Total Stockholders' Equity
Series C convertible preferred stock
STOCKHOLDERS' EQUITY:
Preferred stock, value
Total Stockholders' Equity

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	85,141,956	85,141,956
Common stock, shares outstanding	85,141,956	85,141,956
Series B convertible preferred stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued		115
Preferred stock, shares outstanding		115
Preferred stock redemption price per share (in Dollars per share)	$ 1,000	$ 1,000
Series C convertible preferred stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	4,280	4,280
Preferred stock, shares issued	4,276
Preferred stock, shares outstanding	4,276
Preferred stock redemption price per share (in Dollars per share)	$ 1,000	$ 1,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
REVENUES:
License fees	$ 17,188	$ 294
Apparel	30,245
Total revenues	47,433	294
COST OF REVENUES
License fees	625
Apparel	31,325	84
Total cost of revenues	31,950	84
GROSS PROFIT	15,483	210
OPERATING EXPENSES:
Compensation expense	112,292	30,578
Professional fees	698,706	77,933
Product development	19,387	35,019
Research and development	48,602
Insurance expense	21,706
Bad debt recovery	(7,500)	(1,000)
Selling, general and administrative expenses	90,393	17,038
Total operating expenses	983,586	159,568
LOSS FROM OPERATIONS	(968,103)	(159,358)
OTHER INCOME (EXPENSE):
Interest income		3,033
Interest expense	(1,349)	(82,500)
Interest expense - related party		(52)
Net unrealized gain on equity investments	38,750
Total other income (expense)	37,401	(79,519)
NET LOSS	(930,702)	(238,877)
Deemed dividend	(1,403,997)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (2,334,699)	$ (238,877)
NET LOSS PER COMMON SHARE:
Basic and diluted (in Dollars per share)	$ (0.03)	$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and diluted (in Shares)	85,141,956	23,604,207

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series B Preferred Stock	Series C Preferred Stock	Common Stock	Additional Paid In Capital	Accumulated Deficit	Total
Balance, at Dec. 31, 2019			$ 2,631	$ 2,630,551	$ (2,655,804)	$ (22,622)
Balance, (in Shares) at Dec. 31, 2019	115		23,604,207
Net loss					(238,877)	(238,877)
Balance, at Mar. 31, 2020			$ 2,631	2,630,551	(2,894,681)	(261,499)
Balance, (in Shares) at Mar. 31, 2020	115		23,604,207
Balance, at Dec. 31, 2020			$ 8,514	7,034,502	(5,762,321)	1,280,695
Balance, (in Shares) at Dec. 31, 2020			85,141,956
Series C preferred stock issued for cash, net of offering cost				3,794,102		3,794,102
Series C preferred stock issued for cash, net of offering cost (in Shares)		4,276
Deemed dividend upon issuance of preferred stock				1,403,997	(1,403,997)
Common stock warrants granted for services				83,728		83,728
Net loss					(930,702)	(930,702)
Balance, at Mar. 31, 2021			$ 8,514	$ 12,316,329	$ (8,097,020)	$ 4,227,823
Balance, (in Shares) at Mar. 31, 2021		4,276	85,141,956

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (930,702)	$ (238,877)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	83,728
Amortization of debt discount to interest expense		82,500
Amortization of prepaid stock-based expense	101,222
Net unrealized gain on equity investments	(38,750)
Change in operating assets and liabilities:
(Increase) decrease in inventory	(11,181)	453
Increase in prepaid expenses and other current assets - current	(90,539)	(13,034)
Increase in prepaid expenses - non-current	(19,375)
Increase in accounts payable and accrued expenses	110,967	51,297
Increase in accrued interest payable - related party		52
Increase in deferred revenue	482,812
NET CASH USED IN OPERATING ACTIVITIES	(311,818)	(117,609)
CASH FLOWS FROM INVESTING ACTIVITIES:
Collection on note receivable	23,500
NET CASH PROVIDED BY INVESTING ACTIVITIES	23,500
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of preferred stock	3,794,102	15,000
Advance from a related party	2,366
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,796,468	15,000
NET DECREASE IN CASH AND CASH EQUIVALENTS:	3,508,150	(102,609)
CASH AND CASH EQUIVALENTS - beginning of period	1,128,389	111,752
CASH AND CASH EQUIVALENTS - end of period	4,636,539	9,143
Cash paid during the period for:
Interest
Income taxes
Non-Cash investing and financing activities:
Increase in equity investments recorded as deferred revenue pursuant to a patent license agreement	$ 531,250

Organization and Business

Organization and Business	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
ORGANIZATION AND BUSINESS	NOTE 1 – ORGANIZATION AND BUSINESS Silo Pharma, Inc. (formerly Uppercut Brands, Inc.) (the “Company”) was incorporated in the State of New York on July 13, 2010 under the name Gold Swap, Inc. On January 24, 2013, the Company changed its state of incorporation from New York to Delaware. The Company is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. In addition to the Company’s primary focus on psychedelic research, the Company has been engaged in the development of a streetwear apparel brand, NFID. On October 4, 2013, the Company filed a Form N-54A and elected to become a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). In addition, the Company previously elected to be treated for federal income tax purpose as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended, (the “Code”). Through September 29, 2018, the Company met the definition of RIC in accordance with the guidance under Accounting Standards Codification (“ASC”) Topic 946 “ Financial Services – Investment Companies On May 21, 2019, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter, on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Uppercut Brands, Inc. to Silo Pharma, Inc. On April 8, 2020, the Company incorporated a new wholly-owned subsidiary, Silo Pharma Inc., in the State of Florida. The Company has also secured the domain name www.silopharma.com. The Company has been exploring opportunities to expand the Company’s business by seeking to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. In July 2020, through the Company’s newly formed subsidiary, the Company entered into a commercial evaluation license and option agreement with University of Maryland, Baltimore (“UMB”) (see Note 9) pursuant to which, among other things, UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a master license agreement (“Master License Agreement”) with UMB (see Note 9). The Company plans to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand the Company’s business to focus on this new line of business.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 29, 2021. Going Concern These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited condensed consolidated financial statements, the Company had a net loss and cash used in operations of $930,702 and $311,818, respectively, for the three months ended March 31, 2021. Additionally, the Company had an accumulated deficit of $8,097,020 at March 31, 2021 and has generated minimal revenues under its new business plan. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional capital pursuant to debt or equity financings. The Company may seek to raise additional capital through additional debt and/or equity financings to fund its operations in the future; however, no assurance can be provided that the Company will be able to raise additional capital on favorable terms, or at all. If the Company is unable to raise additional capital or secure additional lending in the future to fund its business plan, the Company may need to curtail or cease its operations. On February 9, 2021, the Company entered into securities purchase agreements with certain institutional and accredited investors pursuant to which it sold an aggregate of 4,276 shares of its newly designated Series C Convertible Preferred Stock and warrants to purchase up to 14,253,323 shares of it ss common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering expenses. The closing of the offering occurred on February 12, 2021 (See Note 7). These unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the three months ended March 31, 2021 and 2020 include the collectability of notes receivable, the valuation of the Company’s equity investments, estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants issued with debt and for services , and the fair value of shares issued for services and in settlements. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in which it holds deposits. At March 31, 2021 and December 31, 2020, the Company had cash in excess of FDIC limits of approximately $4,388,000, and approximately $880,000, respectively. Notes Receivable The Company recognizes an allowance for losses on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general and administrative expense. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets - current of $230,408 and $241,091 at March 31, 2021 and December 31, 2020, respectively, consist primarily of costs paid for future services which will occur within a year. Prepaid expenses and other current assets – non-current of $19,375 and $0 at March 31, 2021 and December 31, 2020, respectively, consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees, research and development fees, and insurance which are being amortized over the terms of their respective agreements. Inventory Inventory consisting of raw materials and finished goods are stated at the lower of cost and net realizable value utilizing the first-in, first-out method. A reserve is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected net realizable value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the net realizable value. These reserves shall be recorded based on estimates and included in cost of sales. The Company did not record an inventory write-down of its raw material during the three months ended March 31, 2021. Equity Investments, at Fair Value Realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s carrying value and the net proceeds received from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or losses are recognized in operations as the difference between the carrying value at the beginning of the period and the fair value at the end of the period. Equity Investments, at Cost Equity investments, at cost are comprised mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs and are evaluated for impairment periodically. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers The Company records interest and dividend income on an accrual basis to the extent that the Company expects to collect such amounts. Product sales are recognized when the product is shipped to the customer and title is transferred and are recorded net of any discounts or allowances. For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license agreement (see Note 9). Cost of Revenues The primary components of cost of revenues on apparel include the cost of the product, production costs, warehouse storage costs and shipping fees. The primary components of cost of revenues on license fees include the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid expense to be amortized over the term of the related license agreement (see Note 9). Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation – Stock Compensation Improvements to Employee Share-Based Payment Income Taxes Deferred income tax assets and liabilities arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company follows the provisions of Financial Accounting Standards Board (“FASB”) ASC 740-10, “Uncertainty in Income Taxes”. Certain recognition thresholds must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax positions that meet a “more-likely-than-not” threshold. The Company does not believe it has any uncertain tax positions as of March 31, 2021 and December 31, 2020 that would require either recognition or disclosure in the accompanying unaudited condensed consolidated financial statements. Research and development In accordance with ASC 730-10, “Research and Development-Overall,” Net Loss per Common Share Basic loss per share is computed by dividing net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially dilutive securities which included convertible preferred shares and stock options are excluded from the computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company’s net losses. The following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the three months ended March 31, 2021 and 2020: March 31, March 31, Series A convertible preferred stock - 2,000,000 Series B convertible preferred stock - 575,000 Series C convertible preferred stock 14,253,333 - Convertible notes - 1,650,000 Stock options 300,000 300,000 Warrants 17,353,987 2,225,000 Leases In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842)” Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The pronouncement requires a modified retrospective method of adoption and was effective on January 1, 2019, with early adoption permitted. For the Company’s administrative office lease, the Company analyzed if it would be required to record a lease liability and a right-of-use asset on its condensed consolidated balance sheets at fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. New Accounting Pronouncements Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Fair Value of Financial Instrum

Fair Value of Financial Instruments and Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 3 – FAIR VALUE OF FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS The Company follows ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1- Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2- Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3- Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company analyzes all financial instruments with features of both liabilities and equity under the FASB’s accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. Equity investments, at fair value The Company accounted for certain equity investments at fair value using level 1, level 2 and level 3 valuations. Assets and liabilities measured at fair value on a recurring basis are as follows at March 31, 2021 and December 31, 2020: At March 31, 2021 (Unaudited) At December 31, 2020 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Equity investments, at fair value $ — $ 570,000 $ — $ — — $ — ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. At March 31, 2021, equity investments, at fair value consisted of preferred equity securities of one entity, AIkido Pharma, Inc. (see Note 9). Equity investments are carried at fair value with unrealized gains or losses included in income (expense). Realized gains and losses are determined on a specific identification basis and are included in other income (expense). The Company reviews equity investments, at fair value for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered. The following are the Company’s equity investments, at fair value owned by levels within the fair value hierarchy at March 31, 2021: Level 1 Level 2 Level 3 Total Common Stock $ — $ — $ — $ — Preferred Stock — 570,000 — 570,000 Total Investments $ — $ 570,000 $ — $ 570,000 At March 31, 2021 and December 31, 2020, equity investments, at fair value consisted of the following components: December 31, 2019 December 31, 2020 Equity investments, at original cost $ 531,250 $ — Gross unrealized appreciation 38,750 — Equity investments, at fair market value $ 570,000 $ — Equity Investments, at Cost At March 31, 2021 and December 31, 2020, equity investments, at cost of $200 comprised mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs and are evaluated for impairment periodically.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
INVENTORY	NOTE 4 – INVENTORY At March 31, 2021, and December 31, 2020, inventory, including jackets, t-shirts, sweatshirts, hats and fabric, consisted of the following: March 31, December 31, Raw materials $ 1,285 $ 1,425 Finished goods 43,380 32,059 Inventory $ 44,665 $ 33,484

Notes Receivable

Notes Receivable	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
NOTES RECEIVABLE	NOTE 5 – NOTES RECEIVABLE On September 28, 2018, the Company and Blind Faith Concepts Holdings, Inc. (the “Seller”) executed a two-year promissory note receivable agreement with a principal balance of $200,000 of which $100,000 was funded to the Seller in September 2018 and the remaining $100,000 was funded in October 2018. The promissory note accrued interest at a rate of 6% per annum, and the Company was repaid in interest only payments on a quarterly basis, until the maturity date of September 27, 2020, at which time the full principal and any interest payments was due to the Company. At the time the promissory note receivable agreement was executed, the Company also executed a security interest and pledge agreement with the borrower pursuant to which the borrower pledged all of the assets of its company as security for the performance of the note obligations. On November 2, 2018, the Company and Seller entered into a promissory note agreement (“Promissory Note Agreement”) with a principal balance of $50,000. Pursuant to the Promissory Note Agreement, the $50,000 note was a deposit and credit towards the acquisition of the assets of Lust for Life Group such as inventory, trademarks and logos. Pursuant to the Promissory Note Agreement, since the purchase did not close within 30 days from date of the Promissory Note, the note receivable became immediately due. Through the date of default, the outstanding principal balance accrued interest at an interest rate of 10% per annum payable on a monthly basis. Upon default, the interest rate increased to 18% per annum. As of December 31, 2018, the Company determined that this note receivable was doubtful and accordingly, recorded an allowance for doubtful account and bad debt expense of $50,000. In December 2019, pursuant to claim purchase agreements (“Claim Purchase Agreements”), the Company sold its notes receivable and related interest receivable balances in the aggregate amount of $277,305 to an investor. Pursuant to the Claim Purchase Agreements, the investor agreed to pay the Company the purchase price of $277,305 on the earlier of the payment of six-monthly installments or upon the liquidation of settlement securities of the Seller pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended. The first installment was be made following entry and full effectuation of a court order approving the settlement of the claim which occurred on March 6, 2020 in the United States District Court for the District of Maryland Northern Division. Additionally, on January 6, 2020, the Company and the Seller entered into a settlement agreement related to notes receivable. In lieu of the Company seeking default and foreclosure against the Seller pursuant to the note agreements, the Company received 10,420 shares of the Seller’s convertible Series B Preferred Stock. Since the shares of Series B Preferred Stock have limited marketability, no value was placed on these shares. Between April 2020 and December 2020, the Company collected an aggregate of $30,000 on the notes receivable balance. During the year ended December 31, 2020, the Company recorded a total allowance for doubtful account and bad debt expense of $174,376 (consisting of the principal balance of $146,500 and interest receivable of $27,876) due to slow collection of the installment payments pursuant to the Claim Purchase Agreements. During the year ended December 31, 2020, the Company recorded $9,000 to bad debt recovery for cash payment received on an older note receivable that was previously written off prior to 2019. On March 10, 2021, the Company collected $23,500 related to this note receivable. As of March 31, 2021 and December 31, 2020, notes receivable, net, consisted of the following: March 31, December 31, Principal amounts of notes receivable $ 220,000 $ 250,000 Collections on notes receivables (23,500 ) (30,000) Less: allowance for doubtful accounts (196,500 ) (196,500) Notes receivable, net $ — $ 23,500

Note Payable

Note Payable	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
NOTE PAYABLE	NOTE 6 - NOTE PAYABLE Paycheck Protection Program Funding On April 30, 2020, the Company received federal funding in the amount of $18,900 through the Paycheck Protection Program (the “PPP”). PPP funds had certain restrictions on use of the funding proceeds, and generally must be repaid within two years and accrued interest at a rate of 1% per annum. The PPP loan may, under circumstances, be forgiven. No payment was due by the Company during the nine months period beginning on the date of this note (“Deferral Period”). Commencing one month after the expiration of the Deferral Period, the Company was to pay the lender monthly payments of principal and interest, each in equal amount required to fully amortize by the maturity date. If a payment on this note was more than ten days late, the lender would charge a late fee of up to 5% of the unpaid portion of the regularly scheduled payment. As of March 31, 2021, the principal balance of this note amounted to $18,900 and accrued interest of $174. During the three months ended March 31, 2021, the Company recognized $47 of interest expense. As of As of Principal amount $ 18,900 $ 18,900 Less: current portion (17,837 ) (14,654 ) Note payable - long term portion $ 1,063 $ 4,246 Minimum principal payments under note payable to unrelated parties at March 31, 2021 were as follows: Year ended December 31, 2021 $ 14,654 Year ended December 31, 2022 4,246 Total principal payments $ 18,900 In April 2021, the Company was notified by the Small Business Administration that the principal and accrued interest under the PPP loan has been forgiven in full (see Note 10).

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY (DEFICIT)	NOTE 7 – STOCKHOLDERS’ EQUITY Preferred stock The Company has authorized the issuance of 5,000,000 shares of preferred stock, $0.0001 par value. The Company’s board of directors is authorized, at any time, and from time to time, to provide for the issuance of shares of preferred stock in one or more series, and to determine the designations, preferences, limitations and relative or other rights of the preferred stock or any series thereof. In April 2013, 1,000,000 shares of preferred stock were designated as Series A Convertible Preferred Stock, and in November 2019, 2,000 shares of preferred stock were designated as Series B Convertible Preferred Stock. Certificate of Designation of Series C Convertible Preferred Stock On February 9, 2021 , the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “Certificate of Designations”) with the Delaware Secretary of State, designating 4,280 shares of preferred stock as Series C Convertible Preferred Stock. Designation Dividends . Liquidation Voting Rights Conversion Exercisability . Series C Convertible Preferred Stock Financing On February 9, 2021 (the “Effectiveness Date”), the Company entered into securities purchase agreements (collectively, the “Series C Purchase Agreements”) with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company’s Series C Convertible Preferred Stock and warrants (the “February Warrants”) to purchase up to 14,253,323 shares (the “February Warrant Shares”) of the Company’s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly, the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of these Series C Convertible Preferred Stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $0.30 per share. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. The Series C Convertible Preferred Stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock. The Series C Purchase Agreement also provides that until the 18 month anniversary of the Effectiveness Date, in the event of a subsequent financing (except for certain exempt issuances as provided in the Series C Purchase Agreement) by the Company, each investor will have the right to participate in such subsequent financing up to an amount equal to the investor’s proportionate share of the subsequent financing based on such investor’s participation in the offering on the same terms, conditions and price provided for in the subsequent financing up to an amount equal to 50% of the subsequent financing. In addition, pursuant to the Series C Purchase Agreement, the Company has agreed that neither it nor its subsidiaries will enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents to file any registration statement other than as contemplated pursuant to the Registration Rights Agreement (as defined below) for a period of 90 days from the Effectiveness Date. Furthermore, subject to certain exceptions, the Company is prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of common stock or common stock equivalents involving a Variable Rate Transaction (as defined in the Series C Purchase Agreement). In connection with the offering, the Company entered into separate registration rights agreements (“Registration Rights Agreements”) with the investors pursuant to which the Company agreed to undertake to file a registration statement (the “Registration Statement”) to register the resale of the Registrable Securities (as defined in the Registration Rights Agreement) within ten calendar days following the Effectiveness Date. The Company agreed to use its best efforts to cause the Registration Statement covering the Registrable Securities to be declared effective no later than the 60 th th . The Registration Statement was filed and declared effective in April 2021. In addition, pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 2,850,664 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $0.35 per share, subject to adjustment. The net proceeds of the offering are expected to be used for working capital purposes and to further execute on the Company’s existing business. Common stock Increase in Authorized Shares On March 10, 2021, the Company filed an amendment to its Certificate of Incorporation with the Secretary of State of Delaware to increase the authorized number of shares of common stock of the Company from 100,000,000 shares to 500,000,000 shares. Stock options On January 18, 2021, the board of directors (“Board of Directors” or “Board”) of the Company approved the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan (the “Plan”) to incentivize employees, officers, directors and consultants of the Company and its affiliates. 8,500,000 shares of common stock are reserved and available for issuance under the Plan, provided that certain exempt awards (as defined in the Plan), shall not count against such share limit. The Plan provides for the grant, from time to time, at the discretion of the Company’s Board or a committee thereof, of cash, stock options, including incentive stock options and nonqualified stock options, restricted stock, dividend equivalents, restricted stock units, stock appreciation units and other stock or cash-based awards. The Plan shall terminate on the tenth anniversary of the date of adoption by the Board of Directors. Subject to certain restrictions, the Board of Directors may amend or terminate the Plan at any time and for any reason. An amendment of the Plan shall be subject to the approval of the Company’s stockholders only to the extent required by applicable laws, rules or regulations. On March 10, 2021, the stockholders of the Company approved the Plan. Stock option activities for the three months ended March 31, 2021 are summarized as follows: Number Weighted Weighted Aggregate Balance Outstanding, December 31, 2020 300,000 $ 0.0001 3.5 127,290 Granted/issued — — — — Forfeited — — — — Balance Outstanding, March 31, 2021 300,000 $ 0.0001 3.29 $ 86,970 Exercisable, March 31, 2021 300,000 $ 0.0001 3.29 $ 86,970 Warrants Warrant activities for the three months ended March 31, 2021 are summarized as follows: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance Outstanding, December 31, 2020 — — — — Granted 17,353,987 0.31 5.00 — Forfeited — — — — Balance Outstanding, March 31, 2021 17,353,987 $ 0.31 4.87 $ 22,500 Exercisable, March 31, 2021 17,353,987 $ 0.31 4.87 $ 22,500 On January 18, 2021, the Company granted warrants to purchase up to 250,000 shares of the Company’s common stock in exchange for legal services rendered. The warrants have a term of five years from the date of grant and are exercisable at an exercise price of $0.20 per share. The warrants were valued on the grant date at approximately $0.33 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions: stock price of $0.35 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year, and a risk-free interest rate of 0.46%. During the three months ended March 31, 2021, the Company recorded stock-based compensation of $83,728. On February 9, 2021, the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 14,253,323 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible Preferred Stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $0.30 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 2,850,664 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $0.35 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2021
Risks and Uncertainties [Abstract]
CONCENTRATIONS	NOTE 8 – CONCENTRATIONS Customer concentration For the three months ended March 31, 2021 and 2020, no customer accounted for over 10% of total revenues from apparel sales. For the three months ended March 31, 2021, one licensee accounted for 100% of total revenues related to the Company’s biopharmaceutical operation as compared to no licensees for the three months ended March 31, 2020. Vendor concentrations Generally, the Company purchases substantially all of its raw materials and inventory from two suppliers. The loss of these suppliers may have a material adverse effect on the Company’s results of operations and financial condition. However, the Company believes that, if necessary, alternate vendors could supply similar products in adequate quantities to avoid material disruptions to operations.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Employment Agreement On April 17, 2020, the Company entered into an employment agreement (“Employment Agreement”) with the Company’s Chief Executive Officer (“CEO”) pursuant to which CEO will serve as Chief Executive Officer and Chief Financial Officer of the Company. The term of the Employment Agreement will continue for a period of one year from the date of execution date thereof and automatically renews for successive one-year periods at the end of each term until either party delivers written notice of their intent not to review at least six months prior to the expiration of the then effective term. Pursuant to the terms of the Employment Agreement, the CEO was granted 7,630,949 vested shares of the Company’s common stock in April 2020, and the CEO’s base salary was increased to $120,000. In addition, the CEO shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board. On January 18, 2021, the Company entered into an amendment (the “Amendment”) to the Employment Agreement, effective as of January 1, 2021, pursuant to which the CEO’s base salary was increased from $120,000 per year to $180,000 per year. The Employment Agreement may be terminated by either the Company or CEO at any time and for any reason upon 60 days prior written notice. Upon termination of the Employment Agreement, the CEO shall be entitled to (i) any equity award that has vested prior to the termination date, (ii) reimbursement of expenses incurred on or prior to such termination date and (iii) such employee benefits to which the CEO may be entitled as of the termination date (collectively, the “Accrued Amounts”). The Employment Agreement shall also terminate upon CEO’s death or the Company may terminate the CEO’s employment upon his disability (as defined in the Employment Agreement). Upon the termination of the CEO’s employment for death or disability, the CEO shall be entitled to receive the Accrued Amounts. The Employment Agreement also contains covenants prohibiting the CEO from disclosing confidential information with respect to the Company. Commercial Evaluation License and Option Agreement with the University of Baltimore, Maryland Effective as of July 15, 2020, through the Company’s wholly-owned subsidiary, Silo Pharma, Inc. (see Note 1), the Company entered into a commercial evaluation license and option agreement with UMB pursuant to which UMB has granted the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. In addition, UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect to the subject technology. This agreement originally was set to expire six months from July 15, 2020 but was extended and exercised on January 13, 2021. Both parties may terminate this agreement within thirty days by giving a written notice. In July 2020, the Company paid the license fee of $10,000 to UMB pursuant to this agreement which was recorded in professional fees during the year ended December 31, 2020 since the Company could not conclude that such costs would be recoverable for this early-stage venture. On February 12, 2021, the Company entered into the Master License Agreement with UMB. On February 26, 2021, through the Company’s wholly-subsidiary, Silo Pharma, Inc., the Company entered into a commercial evaluation license and option agreement with UMB pursuant to which UMB has granted the Company an exclusive, non-sublicensable, non-transferable license to with respect to the exploration of the potential use of joint-homing peptides for use in the investigation and treatment of arthritogenic processes. In addition, UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to with respect to the subject technology. This agreement shall expire six months from February 26, 2021, unless sooner terminated. Both parties may terminate this agreement within thirty days by giving a written notice. Pursuant to the agreement, the Company paid the license fee of $10,000 to UMB in March 2021 pursuant to this agreement which was recorded in professional fees during the three months ended March 31, 2021 since the Company could not conclude that such costs would be recoverable for this early-stage venture. Master License Agreement with the University of Baltimore, Maryland On February 12, 2021 (the “Master License Agreement Effective Date”), the Company entered into the Master License Agreement (the “Master License Agreement”) with UMB pursuant to which UMB granted the Company an exclusive, worldwide, sublicensable, royalty-bearing license to certain intellectual property (i) to make, have made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, “Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology” and UMB’s confidential information to develop and perform certain licensed processes for the therapeutic treatment of neuroinflammatory disease. Pursuant to the Master License Agreement, the Company shall pay UMB (i) a license fee (ii) certain event-based milestone payments, (iii) royalty payments depending on net revenues, and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the Master License Agreement Effective Date; and (b) $50,000 on or before the first anniversary of the Master License Agreement Effective Date. The license fee is non-refundable, and is not creditable against any other fee, royalty, or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid the $25,000 license fee on February 17, 2021 and was recorded in prepaid expenses to be amortized over the 15-year term. The Company recognized amortization expense of $625 during the three months ended March 31, 2021. At March 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expenses – non-current amounts $19,375 as reflected in the accompanying condensed consolidated balance sheets. Additionally, the Company agreed to pay certain royalty payments as follows: (i) 3% on sales of Licensed Products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and (ii) 5% on sales of Licensed Products during the applicable calendar year for sales greater than $50,000,000; and Furthermore, the Company agreed to pay UMB minimum royalty payments, as follows: Payment Year $ - Prior to First Commercial Sale $ - Year of First Commercial Sale $ 25,000 First calendar year following the First Commercial Sale $ 25,000 Second calendar year following the First Commercial Sale $ 100,000 Third calendar year following the First Commercial Sale Furthermore, the Company agrees to pay milestone payments, as follows: Payment Milestone $ 50,000 Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product $ 100,000 Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product $ 250,000 Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product $ 500,000 Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product $ 1,000,000 Achievement of First Commercial Sale of Licensed Product The Company shall pay to UMB a percentage of all sublicense income which is receivable by Company or Company affiliates as follows: (a) 25% of sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product. The Master License Agreement will remain in effect on a Licensed Product-by-Licensed Product basis and country-by-country basis until the later of: (a) the last patent covered under the Master License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) 10 years after the first commercial sale of a Licensed Product in that country, unless earlier terminated in accordance with the provisions of the Master License Agreement. The term of the Master License Agreement shall expire 15 years after the Master License Agreement Effective Date in which (a) there were never any patent rights, (b) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity or (c) there was never a first commercial sale of a Licensed Product. Investigator-Sponsored Study Agreement with Maastricht University of the Netherlands On November 1, 2020, the Company entered into an investigator-sponsored study agreement (the “Study Agreement”) with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and lysergic acid diethylamide on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The Study Agreement shall terminate on October 31, 2024, unless earlier terminated pursuant to the terms thereof. The Company shall pay a total fee of 433,885 Euros ($507,602 USD) exclusive of value added tax to be amortized over the four-year term and payment schedule as follows: Payment 1 86,777 Euros ($101,520 USD) Upon signing the Study Agreement and was paid in December 2020 2 86,777 Euros ($101,520 USD) Obtained approval from ethical committee 3 86,777 Euros ($101,520 USD) Data collection has commenced 4 130,166 Euros ($152,281 USD) First half of the participants are tested 5 43,885 Euros ($50,760 USD) Completion of data collection and delivery of final report In December 2020, the Company paid the first payment which was recorded to prepaid expense and other current assets - current. The Company recognized amortization expense of $39,549 during the three months ended March 31, 2021. Investigator-Sponsored Study Agreement with UMB On January 5, 2021, the Company entered into an investigator-sponsored study agreement (the “Sponsored Study Agreement”) with the University of Maryland, Baltimore. The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis (“MS”). More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and progression of experimental autoimmune encephalomyelitis. Pursuant to the Sponsored Study Agreement, the research shall commence on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties. The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. The Company recognized amortization expense of $9,053 during the three months ended March 31, 2021. Patent License Agreement with AIkido Pharma Inc. On January 5, 2021, the Company entered into a patent license agreement (the “Agreement”) with Silo Pharma, Inc., a Florida corporation and wholly-owned subsidiary of the Company (collectively, the “Licensor”) and AIkido Pharma Inc. (“AIkido”), as amended on April 12, 2021, pursuant to which the Licensor granted AIkido an exclusive, worldwide (the “Territory”), sublicensable, royalty-bearing license to certain intellectual property (i) to make, have made, use, provide, import, export, lease, distribute, sell, offer for sale, develop and advertise certain licensed products and (ii) to develop and perform certain licensed processes for the treatment of cancer and symptoms caused by cancer (the “Field of Use”). In addition, the Agreement also provided that, if the Licensor exercised the option granted to it pursuant to its commercial evaluation license and option agreement with UMB, effective as of July 15, 2020, it would grant AIkido a non-exclusive sublicense (the “Right”) to certain UMB patent rights in the field of neuroinflammatory diseases occurring in patients diagnosed with cancer (the “Field”). Pursuant to the Agreement, AIkido agreed to pay the Licensor, among other things, (i) a one-time non-refundable cash payment of $500,000 and (ii) royalty payments equal to 2% of Net Sales (as defined in the Agreement) in the Field of Use in the Territory. In addition, AIkido issued the Licensor 500 shares of its newly designated Series M Convertible Preferred Stock which shall be converted into an aggregate of 625,000 shares of the AIkido’s common stock. Pursuant to the Agreement, the Company is required to prepare file, prosecute, and maintain the licensed patents. Unless earlier terminated, the term of the license to the licensed patents will continue until the expiration or abandonment of all issued patents and filed patent applications within the licensed patents. The Company may terminate the Agreement upon 30 day written notice if AIkido fails to pay any amounts due and payable to the Company or if AIkido or any of its affiliates brings a patent challenge against the Company, assists others in bringing a legal or administrative challenge to the validity, scope, or enforceability of or opposes any of the licensed patents (“Patent Challenge”) against the Company (except as required under a court order or subpoena). AIkido may terminate the Agreement at any time without cause, and without incurring any additional penalty, (i) by providing at least 30 days’ prior written notice and paying the Company all amounts due to it through such termination effective date. Either party may terminate the Agreement for material breaches that have failed to be cured within 60 days after receiving written notice. The Company collected the non-refundable cash payment of $500,000 on January 5, 2021 which will be recorded in deferred revenues to be recognized as revenues over the term of the Agreement. With respect to a vote of AIkido’s stockholders to approve a reverse split of its common stock no later than December 31, 2021 only (“Reverse Stock Split Vote”), each share of the Series M Convertible Preferred Stock shall be entitled to such number of votes equal to 20,000 shares of AIkido’s common stock. In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date that the Reverse Stock Split Vote is approved by AIkido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of AIkido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment. The Company valued the 500 Series M Convertible Preferred stock which is equivalent into AIkido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of AIkido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. Accordingly, the Company recorded a total deferred revenue of $1,031,250 to be recognized as revenues over the 15-year term. The Company recognized revenues of $17,188 during the three months ended March 31, 2021. At March 31, 2021, deferred revenue – current portion amounted $68,750 and deferred revenue – long-term portion amounted $945,312 as reflected in the accompanying condensed consolidated balance sheets. The Right shall be to the full extent permitted by and on terms and conditions required by UMB for a term consistent with the term of patent and technology licenses that UMB normally grants. In the event that the Company exercises its option and executes a license with UMB to the UMB patent rights within 40 days after the execution of such UMB license, for consideration to be agreed upon and paid by AIkido, which consideration shall in no event exceed 110% of any fee payable by the Company to UMB for the right to sublicense the UMB patent rights. The Company shall grant AIkido a nonexclusive sublicense in the United States to the UMB patent rights in the Field, subject to the terms of any UMB license Licensor obtains, including any royalty obligations on sublicensees required under any such sublicense. The option was exercised on January 13, 2021. Accordingly, on April 6, 2021, the Company entered into the Sublicense Agreement with AIkido pursuant to which it granted AIkido a worldwide exclusive sublicense to its licensed patents under the Master License Agreement. (See Note 9 “ Sublicense with AIkido Pharma Inc.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS Sublicense with AIkido Pharma Inc. On April 6, 2021 (the “Sublicense Agreement Effective Date”), the Company entered into the Sublicense Agreement with AIkido pursuant to which the Company granted AIkido an exclusive worldwide sublicense to (i) make, have made, use, sell, offer to sell and import the Licensed Products (as defined below) and (ii) in connection therewith to (A) use an invention known as “Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology” which was sublicensed to the Company pursuant to the Master License Agreement and (B) practice certain patent rights (“Patent Rights”) for the therapeutic treatment of neuroinflammatory disease in cancer patients. “Licensed Products” means any product, service, or process, the development, making, use, offer for sale, sale, importation, or providing of which: (i) is covered by one or more claims of the Patent Rights; or (ii) contains, comprises, utilizes, incorporates, or is derived from the Invention or any technology disclosed in the Patent Rights. Pursuant to the Sublicense Agreement, AIkido agreed to pay us (i) an upfront license fee of $50,000, (ii) the same sales-based royalty payments that the Company is subject to under the Master License Agreement and (iii) total milestone payments of up to $1.9 million. The Sublicense Agreement shall continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of (i) the date of expiration of the last to expire claim of the Patent Rights covering such Licensed Product in such country, (ii) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity, if applicable and (iii) 10 years after the first commercial sale of a Licensed Product in that country, unless terminated earlier pursuant to the terms of the Sublicense Agreement. Furthermore, the Sublicense Agreement shall expire 15 years after the Sublicense Agreement Effective Date with respect to any country in which (i) there were never any Patent Rights, (ii) there was never any data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity or other legally enforceable market exclusivity with respect to a Licensed Product and (ii) there was never a commercial sale of a Licensed Product, unless such agreement is earlier terminated pursuant to its terms. The Company collected the upfront license fee of $50,000 in April 2021. In connection with this Sublicense Agreement, on April 12, 2021, the Company paid $12,500, or 25% sublicense income to UMB pursuant to the Master License Agreement (see Note 9). Amendment to Patent License Agreement with AIkido On April 12, 2021, the Company entered into an amendment to the Patent License Agreement with AIkido dated January 5, 2021 (see Note 9) pursuant to which the parties agreed that AIkido delivered to the Company 500 shares of the Company’s Series M Convertible Preferred Stock which converted into an aggregate of 625,000 restricted shares of AIkido’s common stock. Conversion of Series C Convertible Preferred Stock On April 12, 2021, the Company notified holders of its Series C Convertible Preferred Stock of its election to force the conversion to its Series C Convertible Preferred Stock into shares of the Company’s common stock pursuant to the Certificate of Designations unless such conversion would cause the holder to exceed its beneficial ownership limitation pursuant to the Certificate of Designations. On April 14, 2021, the Company converted 4,049 Paycheck Protection Program Funding In April 2021, the Company was notified by the Small Business Administration that the principal and accrued interest under the PPP loan has been forgiven in full (see Note 6). Joint Venture Agreement with Zylö Therapeutics, Inc. On April 22, 2021 (the “JV Effective Date”), the Company entered into a Joint Venture Agreement (the “JV Agreement”) with Zylö Therapeutics, Inc. (“ZTI”) pursuant to which the parties agreed to form a joint venture entity, to be named Ketamine Joint Venture, LLC (the “Joint Venture”), to, among other things, focus on the clinical development of ketamine using ZTI’s Z-pod™ technology (the “Venture”). Pursuant to the JV Agreement, the Company shall act as the manager (the “Manager”) of the Joint Venture. The Venture shall terminate if the development program does not meet certain specifications and milestones as set forth in the JV Agreement within 30 days of the date set forth in the JV Agreement. Notwithstanding the foregoing, the Manager may, in its sole discretion, terminate the Venture at any time. Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture. Furthermore, pursuant to the terms of the JV Agreement, ZTI shall grant the Joint Venture a sublicense pursuant to its license agreement (the “License Agreement”) with Albert Einstein College of Medicine dated November 27, 2017, in the event that the Company or a third party makes a request indicating that the patented technology (the “Patented Technology”) licensed to ZTI pursuant to the License Agreement is needed to advance the development of the Joint Venture or it is contemplated or determined that the Patented Technology will be sold. Furthermore, pursuant to the JV Agreement, ZTI granted the Company an exclusive option to enter into a separate joint venture for the clinical development of psilocybin using ZTI’s Z-pod™ technology on the same terms and conditions set forth in the JV Agreement, which option shall expire 24 months after the JV Effective Date.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 29, 2021.
Going Concern	Going Concern These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited condensed consolidated financial statements, the Company had a net loss and cash used in operations of $930,702 and $311,818, respectively, for the three months ended March 31, 2021. Additionally, the Company had an accumulated deficit of $8,097,020 at March 31, 2021 and has generated minimal revenues under its new business plan. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional capital pursuant to debt or equity financings. The Company may seek to raise additional capital through additional debt and/or equity financings to fund its operations in the future; however, no assurance can be provided that the Company will be able to raise additional capital on favorable terms, or at all. If the Company is unable to raise additional capital or secure additional lending in the future to fund its business plan, the Company may need to curtail or cease its operations. On February 9, 2021, the Company entered into securities purchase agreements with certain institutional and accredited investors pursuant to which it sold an aggregate of 4,276 shares of its newly designated Series C Convertible Preferred Stock and warrants to purchase up to 14,253,323 shares of it ss common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering expenses. The closing of the offering occurred on February 12, 2021 (See Note 7). These unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the three months ended March 31, 2021 and 2020 include the collectability of notes receivable, the valuation of the Company’s equity investments, estimates for obsolete and slow-moving inventory, estimates of the deemed dividend, valuation allowances for deferred tax assets, the fair value of warrants issued with debt and for services , and the fair value of shares issued for services and in settlements.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 or by the Securities Investor Protection Corporation up to $250,000. To reduce its risk associated with the failure of such financial institutions, the Company evaluates, at least annually, the rating of the financial institutions in which it holds deposits. At March 31, 2021 and December 31, 2020, the Company had cash in excess of FDIC limits of approximately $4,388,000, and approximately $880,000, respectively.
Notes Receivable	Notes Receivable The Company recognizes an allowance for losses on notes receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical bad debt experience, current note receivable aging, and expected future write-offs, as well as an assessment of specific identifiable accounts considered at risk or uncollectible. The expense associated with the allowance for doubtful accounts is recognized as general and administrative expense.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets - current of $230,408 and $241,091 at March 31, 2021 and December 31, 2020, respectively, consist primarily of costs paid for future services which will occur within a year. Prepaid expenses and other current assets – non-current of $19,375 and $0 at March 31, 2021 and December 31, 2020, respectively, consist primarily of costs paid for future services which will occur after a year. Prepaid expenses may include prepayments in cash and equity instruments for consulting, business advisory, legal services, license fees, research and development fees, and insurance which are being amortized over the terms of their respective agreements.
Inventory	Inventory Inventory consisting of raw materials and finished goods are stated at the lower of cost and net realizable value utilizing the first-in, first-out method. A reserve is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected net realizable value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the net realizable value. These reserves shall be recorded based on estimates and included in cost of sales. The Company did not record an inventory write-down of its raw material during the three months ended March 31, 2021.
Equity Investments, at Fair Value	Equity Investments, at Fair Value Realized gain or loss is recognized when an investment is disposed of and is computed as the difference between the Company’s carrying value and the net proceeds received from such disposition. Realized gains and losses on investment transactions are determined by specific identification. Net unrealized appreciation or depreciation is computed as the difference between the fair value of the investment and the cost basis of such investment. Net unrealized gains or losses are recognized in operations as the difference between the carrying value at the beginning of the period and the fair value at the end of the period.
Equity Investments, at Cost	Equity Investments, at Cost Equity investments, at cost are comprised mainly of non-marketable capital stock and stock warrants, are recorded at cost, as adjusted for other than temporary impairment write-downs and are evaluated for impairment periodically.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers The Company records interest and dividend income on an accrual basis to the extent that the Company expects to collect such amounts. Product sales are recognized when the product is shipped to the customer and title is transferred and are recorded net of any discounts or allowances. For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement. Payments received from the licensee that are related to future periods are recorded as deferred revenue to be recognized as revenues over the term of the related license agreement (see Note 9).
Cost of Revenues	Cost of Revenues The primary components of cost of revenues on apparel include the cost of the product, production costs, warehouse storage costs and shipping fees. The primary components of cost of revenues on license fees include the cost of the license fees. Payments made to the licensor that are related to future periods are recorded as prepaid expense to be amortized over the term of the related license agreement (see Note 9).
Stock-based Compensation	Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation – Stock Compensation Improvements to Employee Share-Based Payment
Income Taxes	Income Taxes Deferred income tax assets and liabilities arise from temporary differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending upon the classification of the asset or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company follows the provisions of Financial Accounting Standards Board (“FASB”) ASC 740-10, “Uncertainty in Income Taxes”. Certain recognition thresholds must be met before a tax position is recognized in the financial statements. An entity may only recognize or continue to recognize tax positions that meet a “more-likely-than-not” threshold. The Company does not believe it has any uncertain tax positions as of March 31, 2021 and December 31, 2020 that would require either recognition or disclosure in the accompanying unaudited condensed consolidated financial statements.
Research and development	Research and development In accordance with ASC 730-10, “Research and Development-Overall,”
Net Loss per Common Share	Net Loss per Common Share Basic loss per share is computed by dividing net loss allocable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period using the as-if converted method. Potentially dilutive securities which included convertible preferred shares and stock options are excluded from the computation of diluted shares outstanding if they would have an anti-dilutive impact on the Company’s net losses. The following potentially dilutive shares have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive for the three months ended March 31, 2021 and 2020: March 31, March 31, Series A convertible preferred stock - 2,000,000 Series B convertible preferred stock - 575,000 Series C convertible preferred stock 14,253,333 - Convertible notes - 1,650,000 Stock options 300,000 300,000 Warrants 17,353,987 2,225,000
Leases	Leases In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842)” Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The pronouncement requires a modified retrospective method of adoption and was effective on January 1, 2019, with early adoption permitted. For the Company’s administrative office lease, the Company analyzed if it would be required to record a lease liability and a right-of-use asset on its condensed consolidated balance sheets at fair value upon adoption of ASU 2016-02. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less.
New Accounting Pronouncements	New Accounting Pronouncements Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of anti-dilutive net loss per share	March 31, March 31, Series A convertible preferred stock - 2,000,000 Series B convertible preferred stock - 575,000 Series C convertible preferred stock 14,253,333 - Convertible notes - 1,650,000 Stock options 300,000 300,000 Warrants 17,353,987 2,225,000

Fair Value of Financial Instr_2

Fair Value of Financial Instruments and Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of equity investment fair value components	At March 31, 2021 (Unaudited) At December 31, 2020 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Equity investments, at fair value $ — $ 570,000 $ — $ — — $ —
Schedule of fair value hierarchy	Level 1 Level 2 Level 3 Total Common Stock $ — $ — $ — $ — Preferred Stock — 570,000 — 570,000 Total Investments $ — $ 570,000 $ — $ 570,000
Schedule of equity investment fair value components	December 31, 2019 December 31, 2020 Equity investments, at original cost $ 531,250 $ — Gross unrealized appreciation 38,750 — Equity investments, at fair market value $ 570,000 $ —

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of inventory, including jackets, t-shirts, sweatshirts, hats and fabric	March 31, December 31, Raw materials $ 1,285 $ 1,425 Finished goods 43,380 32,059 Inventory $ 44,665 $ 33,484

Notes Receivable (Tables)

Notes Receivable (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Receivable (Tables) [Line Items]
Schedule of notes receivable	March 31, December 31, Principal amounts of notes receivable $ 220,000 $ 250,000 Collections on notes receivables (23,500 ) (30,000) Less: allowance for doubtful accounts (196,500 ) (196,500) Notes receivable, net $ — $ 23,500

Note Payable (Tables)

Note Payable (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of interest expense	As of As of Principal amount $ 18,900 $ 18,900 Less: current portion (17,837 ) (14,654 ) Note payable - long term portion $ 1,063 $ 4,246
Schedule of minimum principal payments under note payable unrelated parties	Year ended December 31, 2021 $ 14,654 Year ended December 31, 2022 4,246 Total principal payments $ 18,900

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of warrant activities	Number Weighted Weighted Aggregate Balance Outstanding, December 31, 2020 300,000 $ 0.0001 3.5 127,290 Granted/issued — — — — Forfeited — — — — Balance Outstanding, March 31, 2021 300,000 $ 0.0001 3.29 $ 86,970 Exercisable, March 31, 2021 300,000 $ 0.0001 3.29 $ 86,970
Schedule of warrant activities	Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance Outstanding, December 31, 2020 — — — — Granted 17,353,987 0.31 5.00 — Forfeited — — — — Balance Outstanding, March 31, 2021 17,353,987 $ 0.31 4.87 $ 22,500 Exercisable, March 31, 2021 17,353,987 $ 0.31 4.87 $ 22,500

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of UMB minimum royalty payments	Payment Year $ - Prior to First Commercial Sale $ - Year of First Commercial Sale $ 25,000 First calendar year following the First Commercial Sale $ 25,000 Second calendar year following the First Commercial Sale $ 100,000 Third calendar year following the First Commercial Sale
Schedule of milulestone payments	Payment Milestone $ 50,000 Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product $ 100,000 Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product $ 250,000 Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product $ 500,000 Receipt of New Drug Application (“NDA”) (or foreign equivalent) approval for a Licensed Product $ 1,000,000 Achievement of First Commercial Sale of Licensed Product
Schedule of exclusive of value added tax with payment	Payment 1 86,777 Euros ($101,520 USD) Upon signing the Study Agreement and was paid in December 2020 2 86,777 Euros ($101,520 USD) Obtained approval from ethical committee 3 86,777 Euros ($101,520 USD) Data collection has commenced 4 130,166 Euros ($152,281 USD) First half of the participants are tested 5 43,885 Euros ($50,760 USD) Completion of data collection and delivery of final report

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	Feb. 09, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Mar. 10, 2021
Accounting Policies [Abstract]
Net loss		$ (930,702)	$ (238,877)
Cash used in operations		(311,818)	(117,609)
Accumulated deficit		(8,097,020)		$ (5,762,321)
Aggregate shares (in Shares)	4,276				500,000,000
Warrants to purchase shares (in Shares)	14,253,323
Gross proceeds issued	$ 4,276,000
Federal deposit insurance corporation		250,000
Securities investor protection corporation		250,000
FDIC cash limits		4,388,000		880,000
Prepaid expenses and other current assets		230,408		241,091
Inventory write-down		19,375		$ 0
Research and development cost		$ 48,602	$ 0

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock options [Member]
Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]
Anti-dilutive net loss per share	300,000	300,000
Convertible notes [Member]
Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]
Anti-dilutive net loss per share		1,650,000
Warrants [Member]
Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]
Anti-dilutive net loss per share	17,353,987	2,225,000
Series A convertible preferred stock [Member]
Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]
Anti-dilutive net loss per share		2,000,000
Series B convertible preferred stock [Member]
Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]
Anti-dilutive net loss per share		575,000
Series C convertible preferred stock [Member]
Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive net loss per share [Line Items]
Anti-dilutive net loss per share	14,253,333

Fair Value of Financial Instr_3

Fair Value of Financial Instruments and Fair Value Measurements (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Equity investments cost	$ 200	$ 200

Fair Value of Financial Instr_4

Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of equity investments of fair value - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Level 1 [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of equity investments of fair value [Line Items]
Equity investments, at fair value
Level 2 [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of equity investments of fair value [Line Items]
Equity investments, at fair value	570,000
Level 3 [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of equity investments of fair value [Line Items]
Equity investments, at fair value

Fair Value of Financial Instr_5

Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy	Mar. 31, 2021USD ($)
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments	$ 570,000
Common Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments
Preferred Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments	570,000
Level 1 [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments
Level 1 [Member] | Common Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments
Level 1 [Member] | Preferred Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments
Level 2 [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments	570,000
Level 2 [Member] | Common Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments
Level 2 [Member] | Preferred Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments	570,000
Level 3 [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments
Level 3 [Member] | Common Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments
Level 3 [Member] | Preferred Stock [Member]
Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of fair value hierarchy [Line Items]
Total Investments

Fair Value of Financial Instr_6

Fair Value of Financial Instruments and Fair Value Measurements (Details) - Schedule of equity investment fair value components - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Schedule of equity investment fair value components [Abstract]
Equity investments, at original cost	$ 531,250
Gross unrealized appreciation	38,750
Equity investments, at fair market value	$ 570,000

Inventory (Details) - Schedule

Inventory (Details) - Schedule of inventory, including jackets, t-shirts, sweatshirts, hats and fabric - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Schedule of inventory, including jackets, t-shirts, sweatshirts, hats and fabric [Abstract]
Raw materials	$ 1,285	$ 1,425
Finished goods	43,380	32,059
Inventory	$ 44,665	$ 33,484

Notes Receivable (Details)

Notes Receivable (Details) - USD ($)	Mar. 10, 2021	Jan. 06, 2020	Oct. 31, 2018	Dec. 31, 2020	Apr. 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Nov. 02, 2018	Sep. 30, 2018	Sep. 28, 2018
Notes Receivable (Details) [Line Items]
Principal balance				$ 23,500
Notes receivable balance				30,000
Bad debt recovery				9,000
Note receivable	$ 23,500
Promissory Note Receivable Agreement [Member]
Notes Receivable (Details) [Line Items]
Principal balance								$ 50,000	$ 100,000	$ 200,000
Remaining balance of promissory note receivable			$ 100,000
Interest rate										6.00%
Deposit and credit towards the acquisition of the assets								$ 50,000
Allowance for doubtful account and bad debt							$ 50,000
Promissory Note Receivable Agreement [Member] | Minimum [Member]
Notes Receivable (Details) [Line Items]
Interest rate								10.00%
Promissory Note Receivable Agreement [Member] | Maximum [Member]
Notes Receivable (Details) [Line Items]
Interest rate								18.00%
Purchase Agreement [Member]
Notes Receivable (Details) [Line Items]
Principal balance				146,500
Allowance for doubtful account and bad debt				174,376
Notes receivable and interest receivable						$ 277,305
Notes receivable balance					$ 30,000	$ 277,305
Convertible Series B preferred stock (in Shares)		10,420
Interest receivable				$ 27,876

Notes Receivable (Details) - Sc

Notes Receivable (Details) - Schedule of notes receivable - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Schedule of notes receivable [Abstract]
Principal amounts of notes receivable	$ 220,000	$ 250,000
Collections on notes receivables	(23,500)	(30,000)
Less: allowance for doubtful accounts	$ (196,500)	(196,500)
Notes receivable, net		$ 23,500

Note Payable (Details)

Note Payable (Details) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 30, 2020	Mar. 31, 2021	Dec. 31, 2020
Note Payable (Details) [Line Items]
Principal amount		$ 18,900	$ 18,900
Accrued interest		174
Interest expense		$ 47
Paycheck Protection Program [Member]
Note Payable (Details) [Line Items]
Principal amount	$ 18,900
Interest rate	1.00%
Interest-bearing unsecured	5.00%

Note Payable (Details) - Schedu

Note Payable (Details) - Schedule of interest expense - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Schedule of interest expense [Abstract]
Principal amount	$ 18,900	$ 18,900
Less: current portion	(17,837)	(14,654)
Note payable - long term portion	$ 1,063	$ 4,246

Note Payable (Details) - Sche_2

Note Payable (Details) - Schedule of minimum principal payments under note payable unrelated parties	Mar. 31, 2021USD ($)
Schedule of minimum principal payments under note payable unrelated parties [Abstract]
Year ended December 31, 2021	$ 14,654
Year ended December 31, 2022	4,246
Total principal payments	$ 18,900

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) (Details) - USD ($)	Feb. 09, 2021	Feb. 09, 2021	Jan. 18, 2021	Mar. 31, 2021	Mar. 10, 2021	Dec. 31, 2020	Nov. 30, 2020	Apr. 30, 2013
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred stock, shares authorized				5,000,000		5,000,000
Preferred stock, par value (in Dollars per share)				$ 0.0001		$ 0.0001
Preferred stock value (in Dollars)
Common Stock issued for conversion of Redeemable Series A Preferred stock, shares				1,000
Description of preferred stock conversion				The Series C Convertible Preferred Stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible Preferred Stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock.
Warrants term				5 years
Exercise price (in Dollars per share)				$ 0.30
Warrants period date				180 days
Investor invested percentage				50.00%
Obligation percentage				1.00%
Shares of its common stock	4,276	4,276			500,000,000
Convertible long term notes payable (in Dollars)			$ 8,500,000
Issued five-year warrants to purchase		14,253,323
Issued five-year warrants to purchase price per share (in Dollars per share)		$ 4,276
Aggregate of purchase to common stock		2,850,664
Common stock issuable percentage		10.00%
Placement agent warrants, descriptoin				pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 2,850,664 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $0.35 per share, subject to adjustment.
Consulting Agreement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares of its common stock					100,000,000
Common stock service, description			The warrants were valued on the grant date at approximately $0.33 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions: stock price of $0.35 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year, and a risk-free interest rate of 0.46%. During the three months ended March 31, 2021, the Company recorded stock-based compensation of $83,728.
Series A Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred stock, shares authorized								1,000,000
Preferred stock value (in Dollars)				$ 4,280
Description of preferred stock outstanding				A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.
Series B Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred stock, shares authorized				2,000		2,000		2,000
Preferred stock, par value (in Dollars per share)				$ 0.0001		$ 0.0001
Preferred stock value (in Dollars)
Conversion price per share (in Dollars per share)							$ 0.30
Description of preferred stock conversion	the Company entered into securities purchase agreements (collectively, the “Series C Purchase Agreements”) with certain institutional and accredited investors for the sale of an aggregate of 4,276 shares of the Company’s Series C Convertible Preferred Stock and warrants (the “February Warrants”) to purchase up to 14,253,323 shares (the “February Warrant Shares”) of the Company’s common stock for gross proceeds of approximately $4,276,000, before deducting placement agent and other offering expenses of $481,898 which are offset against the proceeds in additional paid in capital. The offering closed on February 12, 2021. Accordingly, the Company recognized a total deemed dividend of $1,403,997 for the beneficial conversion feature in connection with the issuance of these Series C Convertible Preferred Stock.
Exercise price (in Dollars per share)	$ 0.30	$ 0.30
Issued five-year warrants to purchase		5

Stockholders_ Equity (Deficit_3

Stockholders’ Equity (Deficit) (Details) - Schedule of stock options activities - Stock Options [Member] $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Stockholders’ Equity (Deficit) (Details) - Schedule of stock options activities [Line Items]
Number of Options, balance beginning	300,000
Weighted Average Exercise Price, balance beginning (in Dollars per share) | $ / shares	$ 0.0001
Weighted Average Remaining Contractual Term (Years), balance beginning	3 years 6 months
Aggregate Intrinsic Value, balance beginning (in Dollars) | $	$ 127,290
Number of Options, Granted/issued
Weighted Average Exercise Price, Granted/issued (in Dollars per share) | $ / shares
Weighted Average Remaining Contractual Term (Years), Granted/issued
Aggregate Intrinsic Value, Granted/issued
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited (in Dollars per share) | $ / shares
Weighted Average Remaining Contractual Term (Years), Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Options, ending balance	300,000
Weighted Average Exercise Price, ending balance (in Dollars per share) | $ / shares	$ 0.0001
Weighted Average Remaining Contractual Term (Years), ending balance	3 years 105 days
Aggregate Intrinsic Value, ending balance (in Dollars) | $	$ 86,970
Number of Options, Exercisable	300,000
Weighted Average Exercise Price, Exercisable (in Dollars per share) | $ / shares	$ 0.0001
Weighted Average Remaining Contractual Term (Years), Exercisable	3 years 105 days
Aggregate Intrinsic Value, Exercisable (in Dollars) | $	$ 86,970

Stockholders_ Equity (Deficit_4

Stockholders’ Equity (Deficit) (Details) - Schedule of warrant activities - Warrant [Member] $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Stockholders’ Equity (Deficit) (Details) - Schedule of warrant activities [Line Items]
Number of Warrants, beginning balance
Weighted Average Exercise Price, beginning balance (in Dollars per share) | $ / shares
Weighted Average Remaining Contractual Term (Years), beginning balance
Aggregate Intrinsic Value, beginning balance (in Dollars) | $
Number of Warrants, Granted	17,353,987
Weighted Average Exercise Price, Granted (in Dollars per share) | $ / shares	$ 0.31
Weighted Average Remaining Contractual Term (Years), Granted	5 years
Number of Warrants, Forfeited
Weighted Average Exercise Price, Forfeited (in Dollars per share) | $ / shares
Weighted Average Remaining Contractual Term (Years), Forfeited
Aggregate Intrinsic Value, Forfeited
Number of Warrants, ending balance	17,353,987
Weighted Average Exercise Price, ending balance (in Dollars per share) | $ / shares	$ 0.31
Weighted Average Remaining Contractual Term (Years), ending balance	4 years 317 days
Aggregate Intrinsic Value, ending balance (in Dollars) | $	$ 22,500
Number of Warrants, Exercisable	17,353,987
Weighted Average Exercise Price, Exercisable (in Dollars per share) | $ / shares	$ 0.31
Weighted Average Remaining Contractual Term (Years), Exercisable	4 years 317 days
Aggregate Intrinsic Value, Exercisable (in Dollars) | $	$ 22,500

Concentrations (Details)

Concentrations (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Concentrations (Details) [Line Items]
Number of suppliers	2
Total revenue
Concentrations (Details) [Line Items]
Percentage of total sales	10.00%	10.00%
One Licensee [Member] | Total revenue
Concentrations (Details) [Line Items]
Percentage of total sales	100.00%

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Jan. 05, 2021	Nov. 01, 2020USD ($)	Nov. 01, 2020EUR (€)	Dec. 31, 2021shares	Apr. 17, 2021	Feb. 26, 2021USD ($)	Jul. 31, 2020USD ($)	Mar. 31, 2021USD ($)shares
Commitments and Contingencies (Details) [Line Items]
Employment agreement, description					the CEO was granted 7,630,949 vested shares of the Company’s common stock in April 2020, and the CEO’s base salary was increased to $120,000. In addition, the CEO shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board. On January 18, 2021, the Company entered into an amendment (the “Amendment”) to the Employment Agreement, effective as of January 1, 2021, pursuant to which the CEO’s base salary was increased from $120,000 per year to $180,000 per year.
License fee						$ 10,000	$ 10,000
License agreement, description								the Company shall pay UMB (i) a license fee (ii) certain event-based milestone payments, (iii) royalty payments depending on net revenues, and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the Master License Agreement Effective Date; and (b) $50,000 on or before the first anniversary of the Master License Agreement Effective Date. The license fee is non-refundable, and is not creditable against any other fee, royalty, or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid the $25,000 license fee on February 17, 2021 and was recorded in prepaid expenses to be amortized over the 15-year term. The Company recognized amortization expense of $625 during the three months ended March 31, 2021. At March 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expenses – non-current amounts $19,375 as reflected in the accompanying condensed consolidated balance sheets.
Royalty payments, description								the Company agreed to pay certain royalty payments as follows: (i)3% on sales of Licensed Products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and (ii)5% on sales of Licensed Products during the applicable calendar year for sales greater than $50,000,000; and Furthermore, the Company agreed to pay UMB minimum royalty payments, as follows:
Sublicense income, description								(a) 25% of sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product.
Commercial sale term								10 years
License agreement expire								15 years
Total fee		$ 507,602	€ 433,885
Amortization expense								$ 39,549
Sponsored study agreement, description	The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. The Company recognized amortization expense of $9,053 during the three months ended March 31, 2021.
Non-refundable cash payment								$ 500,000
Net sale percentage								2.00%
Licensor share (in Shares) | shares								500
Aggregate of converted shares (in Shares) | shares								625,000
Reverse stock split vote, description								(i) the date that the Reverse Stock Split Vote is approved by AIkido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of AIkido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment. The Company valued the 500 Series M Convertible Preferred stock which is equivalent into AIkido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of AIkido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.
Deferred revenue								$ 1,031,250
Revenue term								15
Recognized revenues								$ 17,188
Deferred revenue – current portion								68,750
Deferred revenue – long-term portion								$ 945,312
Consideration fee payable percentage								110.00%
Forecast [Member]
Commitments and Contingencies (Details) [Line Items]
Number of voting shares (in Shares) | shares				20,000

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments	3 Months Ended
	Mar. 31, 2021USD ($)
Payment One [Member]
Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]
Payment
Year	Prior to First Commercial Sale
Payment Two [Member]
Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]
Payment
Year	Year of First Commercial Sale
Payment Three [Member]
Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]
Payment	$ 25,000
Year	First calendar year following the First Commercial Sale
Payment Four [Member]
Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]
Payment	$ 25,000
Year	Second calendar year following the First Commercial Sale
Payment Five [Member]
Commitments and Contingencies (Details) - Schedule of UMB minimum royalty payments [Line Items]
Payment	$ 100,000
Year	Third calendar year following the First Commercial Sale

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of milulestone payments	3 Months Ended
	Mar. 31, 2021USD ($)
Payment One [Member]
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]
Payment	$ 50,000
Milestone	Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product
Payment Two [Member]
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]
Payment	$ 100,000
Milestone	Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product
Payment Three [Member]
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]
Payment	$ 250,000
Milestone	Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product
Payment Four [Member]
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]
Payment	$ 500,000
Milestone	Receipt of New Drug Application ("NDA") (or foreign equivalent) approval for a Licensed Product
Payment Five [Member]
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]
Payment	$ 1,000,000
Milestone	Achievement of First Commercial Sale of Licensed Product

Commitments and Contingencies_5

Commitments and Contingencies (Details) - Schedule of exclusive of value added tax with payment	3 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021EUR (€)
Payment One [Member]
Registration Payment Arrangement [Line Items]
Payment	$ 101,520	€ 86,777
Payment description	Upon signing the Study Agreement and was paid in December 2020	Upon signing the Study Agreement and was paid in December 2020
Payment Two [Member]
Registration Payment Arrangement [Line Items]
Payment	$ 101,520	€ 86,777
Payment description	Obtained approval from ethical committee	Obtained approval from ethical committee
Payment Three [Member]
Registration Payment Arrangement [Line Items]
Payment	$ 101,520	€ 86,777
Payment description	Data collection has commenced	Data collection has commenced
Payment Four [Member]
Registration Payment Arrangement [Line Items]
Payment	$ 152,281	€ 130,166
Payment description	First half of the participants are tested	First half of the participants are tested
Payment Five [Member]
Registration Payment Arrangement [Line Items]
Payment	$ 50,760	€ 43,885
Payment description	Completion of data collection and delivery of final report	Completion of data collection and delivery of final report

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Apr. 14, 2021	Apr. 12, 2021	Apr. 30, 2021	Mar. 31, 2021	Mar. 10, 2021	Feb. 09, 2021
Subsequent Events (Details) [Line Items]
Upfront license fee				$ 50,000
Milestone payments				$ 1.9
License term				10 years
Agreement expire, term				15 years
Shares issued (in Shares)					500,000,000	4,276
Agreement description				(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture.
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Upfront license fee			$ 50,000
Company paid			$ 12,500
Sublicense income percentage			25.00%
Shares issued (in Shares)		500
Restricted shares (in Shares)		625,000
Converted shares description	the Company converted 4,049 Series C Convertible Preferred Stock into 13,495,014 shares of common stock. Currently, there are 227 shares of the Company’s Series C Convertible Preferred Stock which remain outstanding.